Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objectives: Treating biofilm infections successfully is a challenge. We hypothesized that biofilms may be considered as independent compartments with particular pharmacokinetics. We therefore studied the pharmacokinetics and pharmacodynamics of tobramycin in a seaweed alginate-embedded biofilm model. Methods: Seaweed alginate beads containing Pseudomonas aeruginosa were cultured in LB medium, sampled at day 1, 3, 5 or 7 and examined for the effect of treatment with tobramycin for 30 min. Treated beads were homogenized and the number of cfu was determined. The antibiotic concentration in the solution of homogenized beads was measured. Finally, beads were examined for live cells by Syto9 staining and for dead cells by propidium iodide staining using a confocal laser scanning microscope. Results: The antibiotic level in each bead was relatively stable (range 30–42 mg/L; MIC = 1.5 mg/L). There were fewer cfu in the tobramycin-treated beads than the non-treated beads (P < 0.016) and bacterial killing was reduced as the culture period increased from 1 to 7 days. Throughout the study period, increasing size and more superficial positioning of the microcolonies within the beads were demonstrated by confocal laser scanning microscopy. More dead cells (measured by propidium iodide staining) were observed in the treated group of beads, which supports the results obtained by culture. Conclusions: The present study, simulating the clinical pharmacokinetics of tobramycin, demonstrates fast absorption of tobramycin in an in vitro biofilm model. In addition, this model system enables parallel investigation of pharmacokinetics and pharmacodynamics, providing a model for testing new treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“biofilms have been proposed as a third pharmacological compartment, in addition to the blood and the target tissue of the infection [31,32].”
From Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bjarnsholt, T., Alhede, M., Alhede, M., Eickhardt-Sørensen, S. R., Moser, C., Kühl, M., Jensen, P. Ø., & Høiby, N. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.06.002 · Cited by 764
Self-citationTseng, B. S., Zhang, W., Harrison, J. J., Quach, T. P., Song, J. L., Penterman, J., Singh, P. K., Chopp, D. L., Packman, A. I., & Parsek, M. R. (2013) · Environmental Microbiology · doi:10.1111/1462-2920.12155 · Cited by 466
Research works printed but not linked: 28
- Burmolle, 2010, Biofilms in chronic infections—a matter of opportunity—monospecies biofilms in multispecies infections, FEMS Immunol Med Microbiol, 59, 324, 10.1111/j.1574-695X.2010.00714.x · DOI · Paper page
- Stewart, 2002, Mechanisms of antibiotic resistance in bacterial biofilms, Int J Med Microbiol, 292, 107, 10.1078/1438-4221-00196 · DOI · Paper page
- Costerton, 1999, Bacterial biofilms: a common cause of persistent infections, Science, 284, 1318, 10.1126/science.284.5418.1318 · DOI · Paper page
- Hall-Stoodley, 2009, Evolving concepts in biofilm infections, Cell Microbiol, 11, 1034, 10.1111/j.1462-5822.2009.01323.x · DOI · Paper page
- Jensen, 2010, The immune system vs. Pseudomonas aeruginosa biofilms, FEMS Immunol Med Microbiol, 59, 292, 10.1111/j.1574-695X.2010.00706.x · DOI · Paper page
- Costerton, 2011, New methods for the detection of orthopedic and other biofilm infections, FEMS Immunol Med Microbiol, 61, 133, 10.1111/j.1574-695X.2010.00766.x · DOI · Paper page
- Hall-Stoodley, 2012, Towards diagnostic guidelines for biofilm-associated infections, FEMS Immunol Med Microbiol, 65, 127, 10.1111/j.1574-695X.2012.00968.x · DOI · Paper page
- Romling, 2012, Biofilm infections, their resilience to therapy and innovative treatment strategies, J Intern Med, 272, 541, 10.1111/joim.12004 · DOI · Paper page
- Kiang, 2014, A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring, Clin Pharmacokinet, 53, 695, 10.1007/s40262-014-0152-3 · doi:10.1007/s40262-014-0152-3
- Udy, 2013, Clinical implications of antibiotic pharmacokinetic principles in the critically ill, Intensive Care Med, 39, 2070, 10.1007/s00134-013-3088-4 · DOI · Paper page
- Hoiby, 2011, The clinical impact of bacterial biofilms, Int J Oral Sci, 3, 55, 10.4248/IJOS11026 · DOI · Paper page
- Christophersen, 2012, Bead-size directed distribution of Pseudomonas aeruginosa results in distinct inflammatory response in a mouse model of chronic lung infection, Clin Exp Immunol, 170, 222, 10.1111/j.1365-2249.2012.04652.x · DOI
- Bjarnsholt, 2012, Understanding biofilms—are we there yet, FEMS Immunol Med Microbiol, 65, 125, 10.1111/j.1574-695X.2012.00984.x · doi:10.1111/j.1574-695x.2012.00984.x
- Macia, 2011, Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment, Antimicrob Agents Chemother, 55, 5230, 10.1128/AAC.00617-11 · DOI · Paper page
- Cerca, 2005, Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry, J Antimicrob Chemother, 56, 331, 10.1093/jac/dki217 · DOI · Paper page
- Hengzhuang, 2012, In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection, Antimicrob Agents Chemother, 56, 2683, 10.1128/AAC.06486-11 · DOI · Paper page
- Suci, 1994, Investigation of ciprofloxacin penetration into Pseudomonas aeruginosa biofilms, Antimicrob Agents Chemother, 38, 2125, 10.1128/AAC.38.9.2125 · DOI · Paper page
- Stewart, 2009, Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm, Antimicrob Agents Chemother, 53, 3505, 10.1128/AAC.01728-08 · DOI · Paper page
- Bordi, 2011, Hacking into bacterial biofilms: a new therapeutic challenge, Ann Intensive Care, 1, 19, 10.1186/2110-5820-1-19 · DOI · Paper page
- Shigeta, 1997, Permeation of antimicrobial agents through Pseudomonas aeruginosa biofilms: a simple method, Chemotherapy, 43, 340, 10.1159/000239587 · DOI · Paper page
- Nichols, 1988, Inhibition of tobramycin diffusion by binding to alginate, Antimicrob Agents Chemother, 32, 518, 10.1128/AAC.32.4.518 · DOI · Paper page
- Coquet, 1998, Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin, J Antimicrob Chemother, 42, 755, 10.1093/jac/42.6.755 · DOI · Paper page
- Walters, 2003, Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin, Antimicrob Agents Chemother, 47, 317, 10.1128/AAC.47.1.317-323.2003 · DOI · Paper page
- Xu, 1998, Spatial physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by oxygen availability, Appl Environ Microbiol, 64, 4035, 10.1128/AEM.64.10.4035-4039.1998 · DOI · Paper page
- Chiang, 2013, Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms, Antimicrob Agents Chemother, 57, 2352, 10.1128/AAC.00001-13 · DOI · Paper page
- Okshevsky, 2013, The role of extracellular DNA in the establishment, maintenance and perpetuation of bacterial biofilms, Crit Rev Microbiol, 4, 1
- Berney, 2007, Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLight Kit in combination with flow cytometry, Appl Environ Microbiol, 73, 3283, 10.1128/AEM.02750-06 · DOI · Paper page
- Hengzhuang, 2011, Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms, Antimicrob Agents Chemother, 55, 4469, 10.1128/AAC.00126-11 · DOI · Paper page
Cited by
Antibiotic treatment of biofilm infections
Ciofu, O., Rojo‐Molinero, E., Macià, M. D., & Oliver, A. (2017) · APMIS · doi:10.1111/apm.12673 · Cited by 496
Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections
Olivares, E., Badel-Berchoux, S., Provot, C., Prévost, G., Bernardi, T., & Jehl, F. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02894 · Cited by 187
“This will influence local antibiotic concentration and its metabolization in the biofilm (Cao et al., 2015).”
BackgroundMechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms
Fernández-Billón, M., Llambías-Cabot, A. E., Jordana-Lluch, E., Oliver, A., & Macià, M. D. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100129 · Cited by 170
Soares, A., Alexandre, K., & Etienne, M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.02057 · Cited by 113
Metadata
- Authors
- Cao, B., Christophersen, L., Thomsen, K., Sønderholm, M., Bjarnsholt, T., Jensen, P. Ø., Høiby, N., & Moser, C.
- Affiliations
- 1 Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark
- 2 Institute of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-18
- Volume
- 70
- Issue
- 7
- Pages
- 2057-2063
- ISSN
- 1460-2091
- 0305-7453
- Cited by
- 68
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model. https://app.cochat.ai/papers/10.1093/jac/dkv058
- The paper
- Cao, B., Christophersen, L., Thomsen, K., Sønderholm, M., Bjarnsholt, T., Jensen, P. Ø., Høiby, N., & Moser, C. (2015). Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkv058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.